DAVID W GRYSKA
CIK 1202335 · Executive Vice President, CFO · last filed 2026-06-15
DAVID W GRYSKA is an Executive Vice President, CFO who has filed 117 SEC Form 4 insider transactions across 11 companies since 2007. The most recent filing, for DFTX, was dated Jun 15, 2026. Across all open-market trades the lifetime net is −$23.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.6M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.56M
11
117
-$23.62M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DFTX | Director | 19,900 | $44.39 | $883.4K | $0 | 1 | 2026-06-15 |
| FBRX | Director | 5,941 | $76.61 | $455.1K | $0 | 6 | 2026-06-02 |
| Definium Therapeutics, Inc. (MNMD) Delisted | Director | 19,851 | $15.00 | $297.8K | $38.9K | 5 | 2025-06-16 |
| Seagen Inc. (SGEN) Delisted | Director | 0 | $228.74 | $0 | -$9.71M | 42 | 2023-12-15 |
| AERIE PHARMACEUTICALS INC (AERI) Delisted | Director | 0 | $15.25 | $0 | $0 | 7 | 2022-11-21 |
| GW PHARMACEUTICALS PLC (GWPH) Delisted | Director | — | $218.96 | — | $0 | 2 | 2021-02-24 |
| PDL BIOPHARMA, INC. (PDLI) Delisted | Director | 1,387 | — | — | -$925.8K | 14 | 2020-12-31 |
| INCY | Executive Vice President, CFO | 10,235 | $119.80 | $1.23M | -$9.18M | 17 | 2018-07-18 |
| HYPERION THERAPEUTICS INC (HPTX) Delisted | Director | — | — | — | $0 | 1 | 2013-05-01 |
| CELGENE CORP /DE/ (CELG) Delisted | Chief Financial Officer | 7,526 | — | — | -$3.84M | 20 | 2010-07-15 |
| COTHERIX INC (CTRX) Delisted | Director | — | — | — | $0 | 1 | 2007-01-10 |
Recent Filings
117 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-15 | DFTX | Grant (A) | +4,666 | $0 | EDGAR |
| 2026-06-02 | FBRX | Grant (A) | — | $0 | EDGAR |
| 2025-06-16 | Definium Therapeutics, Inc. (MNMD) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-03-21 | FBRX | Grant (A) | — | $0 | EDGAR |
| 2024-12-05 | Definium Therapeutics, Inc. (MNMD) Delisted | Buy (P) | +2,500 | $17.9K | EDGAR |
| 2024-08-26 | Definium Therapeutics, Inc. (MNMD) Delisted | Buy (P) | +3,500 | $20.9K | EDGAR |
| 2024-08-22 | FBRX | Grant (A) | — | $0 | EDGAR |
| 2024-06-12 | Definium Therapeutics, Inc. (MNMD) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-12-15 | Seagen Inc. (SGEN) Delisted | Disp (D) | −49,003 | -$11.22M | EDGAR |
| 2023-09-20 | FBRX | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.